- Home
- BBNX vs LYEL Comparison
BBNX vs LYEL Comparison
Compare BBNX & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBNX | LYEL |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | 423 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.1M | 490.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BBNX | LYEL |
|---|---|---|
| Price | $10.37 | $21.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $26.22 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 1.1M | 96.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $61,000.00 |
| Revenue This Year | $34.99 | N/A |
| Revenue Next Year | $34.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.89 | $0.39 |
| 52 Week High | $32.71 | $45.00 |
Technical Indicators
Market Signals| Indicator | BBNX | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 25.83 | 41.37 |
| Support Level | N/A | $21.27 |
| Resistance Level | $15.53 | $27.30 |
| Average True Range (ATR) | 0.67 | 1.85 |
| MACD | 0.08 | 0.08 |
| Stochastic Oscillator | 11.22 | 9.38 |
Price Performance
Historical ComparisonAbout BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.